Autopsy report · NCT01103180

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

“Funding withdrawn due to inability to accrue”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 4 years 2 months before it stopped.
• 70 participants enrolled.
• Results were posted on the registry 4 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Chicago

Sponsor type

University, hospital or other

Conditions

Borderline Personality Disorder

Interventions

Escitalopram

Participants

70

Sites

1

Countries

United States

Trials that died the same way

• The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU
  “Withdrawn due to no funding” (88% match in meaning)
• Walnuts and Glucose Variability
  “Funding withdrawn” (84% match in meaning)
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  “funding was withdrawn” (84% match in meaning)
• Hydroxychloroquine Efficacy in Chronic Urticaria
  “withdrawn, not funded” (81% match in meaning)
• Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
  “Withdrawal of funding” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.